Press Release Media Contacts: IB Communications Tel +44 (0)20 89434685 immutep@ibcomms.agency Immutep announces investigator-initiated Phase II trial

Immutep announces investigator-initiated Phase II trial evaluating LAG-3 candidate eftilagimod alpha (efti) in soft tissue sarcoma Expansion of the efti clinical development pipeline with a new Phase II settingEfti Phase II trial awarded EUR 1.5M (AUD 2.2M) in funding as part of the Polish Medical Research Agen...

Related Keywords

Australia ,Sydney ,New South Wales ,Poland ,Warsaw ,L67 ,Polish ,Katarzyna Kozak ,Frederic Triebel ,Pawel Sobczuk ,Marc Voigt ,Maria Sklodowska Curie National Research Institute Of Oncology ,Research Agency ,Curie National Research Institute Of Oncology ,Department Of Soft Tissue Bone Sarcoma ,Nasdaq ,Maria Sklodowska Curie National Research Institute ,Institute For Drug ,Polish Medical Research Agency ,Immutep Limited ,Material Transfer Agreement ,Curie National Research Institute ,Polish State Institute ,Drug Control ,Principal Investigators ,Bone Sarcoma ,Sklodowska Curie National Research Institute ,Medical Oncology Fellow ,Co Principal Investigator ,